ARCT-032 Cystic Fibrosis Trial: Thermo Fisher and Arcturus Join Forces
Thermo Fisher Scientific and Arcturus Therapeutics have announced a landmark strategic collaboration to advance the ARCT-032 cystic fibrosis trial into Phase III development. The partnership, structured around Thermo Fisher’s Accelerator Drug Development solutions, combines integrated manufacturing, clinical research, and commercial readiness services — positioning ARCT-032 as one of the most closely watched mRNA-based treatments for cystic fibrosis currently in development. This alliance signals a major step forward in the effort to bring next-generation RNA therapies to patients who have long depended on limited treatment options.
What Is ARCT-032 and Why Does It Matter?
ARCT-032 is an investigational messenger RNA (mRNA) therapy developed by Arcturus Therapeutics, specifically designed to treat cystic fibrosis (CF) — a life-threatening genetic disorder that affects the lungs, digestive system, and other organs. Unlike traditional small-molecule drugs, mRNA therapies work by instructing the body’s own cells to produce functional proteins, offering a potentially transformative approach for CF patients whose underlying genetic mutations cannot be addressed by existing modulators.
The Science Behind Arcturus’ mRNA Approach
Arcturus Therapeutics has built its pipeline around its proprietary LUNAR lipid-mediated delivery platform, which enables targeted mRNA delivery to the lungs — a notoriously difficult organ to reach via systemic administration. ARCT-032 leverages this platform to deliver corrective genetic instructions directly to airway epithelial cells, aiming to restore the function of the defective CFTR protein responsible for cystic fibrosis symptoms.
This approach is particularly significant for the large subset of CF patients who carry mutations not covered by current CFTR modulator drugs. If Phase III data proves positive, ARCT-032 could represent a mutation-agnostic treatment option — one that benefits a far broader patient population than therapies targeting specific genetic variants.
Terms of the Thermo Fisher and Arcturus Partnership
The collaboration agreement positions Thermo Fisher as the primary strategic partner for ARCT-032’s journey from late-stage clinical development to potential commercialisation. The scope of the deal is broad and multifaceted, touching every operational layer of the drug’s development lifecycle.
Accelerator Drug Development: Thermo Fisher’s Integrated Model
At the center of the partnership is Thermo Fisher’s Accelerator Drug Development platform — an integrated suite of services that combines contract development and manufacturing organisation (CDMO) capabilities with clinical research execution and commercial launch readiness. Rather than working with multiple vendors across each development phase, Arcturus will rely on a single, unified partner to manage the complexity of Phase III operations.
Under the agreement, Thermo Fisher will provide:
- Integrated manufacturing services for clinical-stage and, eventually, commercial-scale production of ARCT-032
- Clinical research services through its PPD clinical research business, which will manage the Phase III trial if Phase II data proves successful
- Commercial readiness support to enable a seamless transition from trial completion to market launch, pending regulatory authorisation
Subject to regulatory approval, Thermo Fisher is also expected to secure exclusive commercial manufacturing rights for ARCT-032 under a future commercial agreement — a provision that underscores both companies’ long-term confidence in the therapy.
Leadership Voices: What Arcturus and Thermo Fisher Are Saying
Arcturus Therapeutics President and CEO Joseph Payne highlighted the strategic rationale behind the deal. He pointed to Thermo Fisher’s CDMO capabilities, global infrastructure, and proven expertise in managing complex mRNA programmes from Phase III through potential commercialisation. He noted that these capabilities directly align with Arcturus’ goal of efficiently advancing its cystic fibrosis programme and preparing for potential commercial supply.
Thermo Fisher Biopharma Services Executive Vice President and President Mike Shafer offered a broader industry perspective. He observed that biotechnology innovators increasingly seek strategic collaborators capable of supporting complex development programmes across both clinical and commercial stages. He described the Arcturus collaboration as a demonstration of the value of Thermo Fisher’s integrated model — one that simplifies development, reduces operational complexity, and accelerates the delivery of innovative therapies to patients.
PPD Clinical Research Business: A Proven Phase III Executor
Thermo Fisher’s PPD clinical research business brings decades of global trial execution experience to the collaboration. Should ARCT-032 progress beyond Phase II, PPD will serve as the operational backbone of the Phase III programme — coordinating site management, patient recruitment, data management, and regulatory submission support across international markets.
This is not PPD’s first involvement in a high-profile mRNA programme. The business has supported a growing portfolio of RNA-based therapeutics, giving it relevant process knowledge and regulatory familiarity that smaller biotech firms typically cannot replicate in-house.
Phase II Results Will Be the Critical Gate
The Phase III collaboration is explicitly contingent on positive outcomes from the ongoing Phase II trial of ARCT-032. This conditional structure is standard in large pharma-biotech alliances, but it also reflects the scientific uncertainty still inherent in mRNA pulmonary delivery — a therapeutic modality that has proven difficult to translate clinically despite strong preclinical data.
mRNA Therapies for Pulmonary Disease: A Competitive Landscape
The ARCT-032 cystic fibrosis trial enters a competitive but still largely unproven space. While mRNA technology gained global recognition through COVID-19 vaccines, its application to chronic pulmonary disease involves fundamentally different challenges: repeated dosing, sustained lung expression, immune tolerance, and formulation stability all require careful management.
Several other biotechnology firms are pursuing inhaled or nebulised mRNA approaches for respiratory conditions, making the Phase III results for ARCT-032 a closely watched bellwether for the broader field. A successful Phase III readout would not only validate the ARCT-032 programme but could significantly accelerate investor and regulatory confidence in inhaled mRNA as a platform.
Thermo Fisher’s Expanding Role in RNA Therapeutics Manufacturing
The ARCT-032 partnership is part of a broader strategic pivot by Thermo Fisher toward RNA therapeutics manufacturing. The company has invested substantially in mRNA production capacity over the past several years, with facilities across North America, Europe, and Asia capable of supporting both small-scale clinical manufacturing and large-scale commercial production.
This infrastructure investment positions Thermo Fisher to serve as a long-term manufacturing backbone for the growing class of RNA-based medicines — not just for ARCT-032, but for the broader wave of mRNA, siRNA, and antisense oligonucleotide therapies moving through late-stage pipelines globally.
Notably, Thermo Fisher’s PPD business introduced the Clinical Trial Carbon Calculator in October 2025, a tool designed to help research sponsors and biopharmaceutical companies estimate and minimise the environmental footprint of clinical trials. This innovation reflects Thermo Fisher’s broader commitment to sustainable trial operations — a factor increasingly considered in sponsor partnership decisions.
What This Means for Cystic Fibrosis Patients
For the approximately 160,000 people living with cystic fibrosis worldwide, the advancement of ARCT-032 into a Phase III programme represents genuine cause for optimism. Current CFTR modulators — including highly effective combination therapies — have transformed outcomes for patients with specific mutations. However, a meaningful segment of the CF population remains without effective disease-modifying options.
An mRNA-based therapy like ARCT-032, if it succeeds clinically, could eventually offer a mutation-agnostic treatment pathway — one that bypasses the genetic targeting constraints of current modulators entirely. The Thermo Fisher partnership, with its combined manufacturing and clinical execution capabilities, is designed to accelerate that path from clinical proof-of-concept to regulatory approval and commercial availability.
